Drug Profile
Research programme: matriptase inhibitors - Aurigene Oncology
Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Small molecules
- Mechanism of Action Matriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in India
- 02 Apr 2013 Preclinical trials in Osteoarthritis in India (unspecified route)